Genetic bases and clinical manifestations of coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) deficiency
-
- Maria Andrea Desbats
- Clinical Genetics Unit, Department of Woman and Child Health University of Padova Via Giustiniani 3 Padova 35128 Italy
-
- Giada Lunardi
- Clinical Genetics Unit, Department of Woman and Child Health University of Padova Via Giustiniani 3 Padova 35128 Italy
-
- Mara Doimo
- Clinical Genetics Unit, Department of Woman and Child Health University of Padova Via Giustiniani 3 Padova 35128 Italy
-
- Eva Trevisson
- Clinical Genetics Unit, Department of Woman and Child Health University of Padova Via Giustiniani 3 Padova 35128 Italy
-
- Leonardo Salviati
- Clinical Genetics Unit, Department of Woman and Child Health University of Padova Via Giustiniani 3 Padova 35128 Italy
抄録
<jats:title>Abstract</jats:title><jats:p>Coenzyme Q<jats:sub>10</jats:sub> is a remarkable lipid involved in many cellular processes such as energy production through the mitochondrial respiratory chain (RC), beta‐oxidation of fatty acids, and pyrimidine biosynthesis, but it is also one of the main cellular antioxidants. Its biosynthesis is still incompletely characterized and requires at least 15 genes. Mutations in eight of them (<jats:italic>PDSS1, PDSS2, COQ2, COQ4, COQ6, ADCK3, ADCK4,</jats:italic> and <jats:italic>COQ9</jats:italic>) cause primary CoQ<jats:sub>10</jats:sub> deficiency, a heterogeneous group of disorders with variable age of onset (from birth to the seventh decade) and associated clinical phenotypes, ranging from a fatal multisystem disease to isolated steroid resistant nephrotic syndrome (SRNS) or isolated central nervous system disease. The pathogenesis is complex and related to the different functions of CoQ<jats:sub>10</jats:sub>. It involves defective ATP production and oxidative stress, but also an impairment of pyrimidine biosynthesis and increased apoptosis. CoQ<jats:sub>10</jats:sub> deficiency can also be observed in patients with defects unrelated to CoQ<jats:sub>10</jats:sub> biosynthesis, such as RC defects, multiple acyl‐CoA dehydrogenase deficiency, and ataxia and oculomotor apraxia.</jats:p><jats:p>Patients with both primary and secondary deficiencies benefit from high‐dose oral supplementation with CoQ<jats:sub>10</jats:sub>. In primary forms treatment can stop the progression of both SRNS and encephalopathy, hence the critical importance of a prompt diagnosis. Treatment may be beneficial also for secondary forms, although with less striking results.</jats:p><jats:p>In this review we will focus on CoQ<jats:sub>10</jats:sub> biosynthesis in humans, on the genetic defects and the specific clinical phenotypes associated with CoQ<jats:sub>10</jats:sub> deficiency, and on the diagnostic strategies for these conditions.</jats:p>
収録刊行物
-
- Journal of Inherited Metabolic Disease
-
Journal of Inherited Metabolic Disease 38 (1), 145-156, 2014-08-05
Wiley